baber/WOPTO huggingface dataset:
Patent NZ-510690-A (NZ)
Title: Methods for administration of antibiotics
Inventor: OLESON FREDERICK B
IPC: A61K38/08
Filed: 1999-09-24
Abstract: Methods for administering a therapeutically effective amount of daptomycin while minimising skeletal muscle toxicity.  The methods involve administering daptomycin at a dosing interval of 24 hours or greater and at a concentration of 7-75 mg/kg.  This long dosing interval minimises skeletal muscle toxicity and allows for higher peak concentrations of daptomycin, which maintains daptomycin efficacy.   Also described are pharmaceutical compositions for use in this method.  Further described is the use of a lipoprotein antibiotic in the manufacture of a medicament for treating a bacterial infection in a human involving the described method of administration.
Patent NZ-518271-A (NZ)
Title: Method and system for redeeming product marketing rebates
Inventor: DEVLIN EDWARD A
IPC: G06Q20/40
Filed: 2000-09-15
Abstract: A system and method for processing product marketing rebate claims submitted by a consumer in satisfaction of a rebate offer, the consumer having purchased designated products in a qualified transaction recorded by a point-of-sale data processing and storage system that issues a receipt containing a corresponding transaction serial number (100). The method comprises providing a designated site of a computer information network (110) and accessible by the consumer, and receiving a rebate claim on the designated site. The rebate claim comprises (i) the transaction serial number corresponding to the qualified transaction, and (ii) identifying information corresponding to the consumer. The transaction serial number and the identifying information is stored as a stored data record (130). An electronic file transfer is received from the point-of-sale data processing and storage system comprising purchase data records, each record comprising the list of products purchased and the transaction serial number for a qualified transaction in which at least one designated product was purchased (140). Each stored data record is associated with a purchase data record having an identical serial number, and the records are processed to validate the rebate claim (150). Finally, the value of the rebate offer is transferred to the consumer (160). Consumer access by the designated site may be via the global computer information network or by telephone, and may also optionally integrate paper-based and smart/credit/debit-card-based rebate claims. A system for performing the above method is also claimed, as is a method for making a rebate claim prior to or simultaneously with a purchase.
Patent NZ-519020-A (NZ)
Title: Method and system for assay and treatment of mycotoxins and aflatoxins during processing of tobacco products
Inventor: LANE KERRY SCOTT
IPC: C07D401/04
Filed: 1999-10-18
Abstract: A process and system for continuous assay (160) and removal of toxins (410) from tobacco is described. Products such as tobacco contaminated with mycotoxins, particularly aflatoxins, and benzpyrene and its precursors, are subjected to treatment, generally in a solvent medium, to decontaminate the tobacco of the toxin. Continuous monitoring (160) of all harmful toxins eluted from the cleaning solvent (150) is performed by immunoantibody ultraviolet fluorescence, for example. A quality-control process ensures removal of harmful toxins from tobacco before further processing. Decontamination of extracted solvent streams and re-additives ensures safe reuse or disposal of the solvents and re-additives.
Patent NZ-526591-A (NZ)
Title: Production of metal oxide particles with nano-sized grains
Inventor: TALBOT PETER CADE
IPC: C01F17/241
Filed: 2001-11-21
Abstract: A method of producing particles having nano-sized grains, the method comprising the steps of: (a) preparing a solution containing one or more metal cations; (b) mixing the solution from step (a) with a surfactant under conditions such that micelles are formed within the solution to thereby form a micellar liquid; and (c) heating the micellar liquid formed in step (b) to form metal oxide, the heating step being undertaken at room temperature and for a period of time to remove the surfactant and thereby form metal oxide particles having a disordered pore structure.
Patent NZ-528371-A (NZ)
Title: Massage device
Inventor: KENNEDY MELVIN R
IPC: A61H23/04
Filed: 2003-09-22
Abstract: A massage device (10), comprising: a handle (14); a head (12) pivotably coupled to the handle (14), the head (12) having at least one chamber and at least one massage head (22) adapted to contact a skin surface of a user; at least one impeller (42) positioned in the at least one chamber and capable of rotating relative to the head (12); at least fluid conduit having at least one outlet (168) positioned proximate to the impeller (42) for contacting a fluid with the at least one impeller (42), wherein the fluid causes the impeller (42) to rotate; and at least one oscillation device (26) disposed in the head (12) and coupled to the impeller (42) for moving the head (12) in an oscillatory motion relative to the handle (14), wherein the at least one oscillation device (26) is substantially shielded from contact by the fluid emitted from the at least one fluid conduit.
Patent NZ-532474-A (NZ)
Title: Animal fetus blood procurement tables and methods
Inventor: PEASE JEFFREY L
IPC: A22B5/04
Filed: 2004-04-22
Abstract: A table system for extracting blood from an animal fetus having a placenta, comprises of a first table top, a first panel atleast partially disposed above the first table top, the panel having a substantially planar first face disposed at an angle in a range between about 45° to about 110° relative to the horizontal, and a plurality of vertically and horizontally spaced apart spikes outwardly projecting from the first face of the first panel.
Patent NZ-538617-A (NZ)
Title: Azaarene derivatives
Inventor: MATSUSHIMA TOMOHIRO
IPC: A61P9/10
Filed: 2003-08-28
Abstract: Compounds (except N1-cyclopropyl-5-((2-(((2-chloroethylamino)carbonyl)amino)-4-pyridyl)oxy)-1H-1-indolecarboximide) represented by general formula (I), and pharmaceutical compositions comprising compounds represented by general formula (I), are disclosed. These compounds are useful as angiogenesis inhibitors. The use of a compound of general formula (I) for the manufacture of an antitumor agent is also described. The tumor may be pancreatic cancer, a gastric cancer, a colon cancer, a breast cancer, a prostate cancer, a lung cancer, a renal cancer, a brain tumor, a blood cancer or an ovarian cancer. The use of a compound of general formula (I), a salt thereof, or a hydrate of the foregoing for the manufacture of: a therapeutic agent for hemangioma a cancer metastasis inhibitor a therapeutic agent for retinal neovascularization or diabetic retinopathy a therapeutic agent for atherosclerosis of a prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective, or a therapeutic agent for an inflammatory disease, is described. The inflammatory disease may be deformant arthritis, rheumatoid arthritis, psoriasis or delayed hypersensitivity reaction.
Patent NZ-539158-A (NZ)
Title: External preparation for inhibiting keloid formation
Inventor: KAWAZOE TAKESHI
IPC: A61P17/02
Filed: 2003-08-26
Abstract: Disclosed is the use of acetylsalicylic acid in the manufacture of a medicament for inhibition of keloid formation.
Patent NZ-542387-A (NZ)
Title: Materials handling container for curing cheese
Inventor: KIDSON CHARLES BRIAN
Filed: 2004-03-30
Abstract: A material handling container (1) used for curing blocks of cheese that are vacuum packed. The container includes a pallet type base (2) with a smooth platform (4) and a plurality of side panels (3). Each side panel is substantially planar and has a bottom edge provided with a platform locating member or lug (12) or pin (37) that engages in an aperture (13, 38) of the platform. There are interlocking corner brackets (18, 40) having a locating pin (41) and locking pin (42) on the top corners of the side panel to releasably attach adjacent said side panels. The material handling container is made of durable and resilient sheet material (10) including such plastics as polypropylene, high density polyethylene and polystyrene attached to a metal frame (6, 7, 8, 9, and 11). The container is collapsible and can be stored and/or transported in a collapsed state.
Patent NZ-546504-A (NZ)
Title: Novel keto-oxadiazole derivatives as cathepsin inhibitors
Inventor: THURAIRATNAM SUKANTHINI
IPC: C07D413/04
Filed: 2004-10-22
Abstract: Disclosed are compounds of formula (Ib), wherein the substituents are as defined in the specification. The compounds are cathepsin inhibitors useful in the treatment of juvenile onset diabetes, multiple sclerosis, pemphigus vulgaris, Graves' disease, myasthenia gravis, systemic lupus erythemotasus, irritable bowel disease, rheumatoid arthritis, Hashimoto's thyroiditis, asthma, obstructive pulmonary disease, emphysema and bronchiolitis.
Patent NZ-554651-A (NZ)
Title: Rekeyable lock cylinder
Inventor: WARD-DOLKAS PAUL C
Filed: 2005-11-07
Abstract: A wafer-type rekeyable lockset is disclosed. The lockset employs wafer assemblies (52) and locking keys (54) to adjustably key the lockset. Each wafer assembly includes a base wafer (120) and a re-settable wafer (122) that may be adjustably coupled to the base wafer. The locking keys are movable between a first position, in which the base and re-settable wafers are coupled to one another, and a second position, in which the base and re-settable wafers are uncoupled from one another. A key having a desired key profile may be employed to set or program the lockset. A method for rekeying a lockset is also provided.
Patent NZ-556317-A (NZ)
Title: Anti-EphB2 antibodies and methods using same
Inventor: MAO WEIGUANG
IPC: A61K39/395
Filed: 2006-01-31
Abstract: Provided is an anti-EphB2 antibody comprising the following hypervariable region (HVR) sequences: (a) HVR-L I comprising sequence KSSQSLLNSGNQENYLA; (b) HVR-L2 comprising sequence GASTRES; (c) HVR-L3 comprising sequence QNDHSYPFT; (d) HVR-Hl comprising sequence SYWMH; (e) HVR-H2 comprising sequence FINPSTGYTDYNQKFKD; and (t) HVR-H3 comprising sequence RLKLLRYAMDY, or comprising the HVR-L1, HVR-L2, HVR-L3, HVR-HI, HVR-H2, and HVR-H3 sequences of the antibody produced by hybridoma cell line having American Tissue Type Culture (ATCC) No. PTA-6606, wherein the antibody specifically binds human EphB2. The antibodies can be conjugated to cancer toxins and used to treat various cancers and tumours.
Patent NZ-563959-A (NZ)
Title: Improved device for cool drying
Inventor: DALLA VALLE MONICA
IPC: B01D53/26
Filed: 2006-06-01
Abstract: Disclosed is a device for cool drying a gas. The device includes a heat exchanger (2) whose primary part is a vaporizer (3) of a cooling circuit (4) which also includes a compressor (6) driven by a motor (5), a control device (16) for the motor, a condenser (7), measuring means (17) for determining the lowest air temperature of the gas to be dried, measuring means (18) for determining the ambient temperature and a flow meter (19). The control device (16) can be switched between a first user mode in which the cooling circuit (4) is only activated when the gas flow exceeds a preset value and a second user mode in which the lowest air temperature is maintained within a certain range by controlling the cooling circuit (4).
Patent NZ-564323-A (NZ)
Title: Bovine ABCG2 gene missense mutation (Y581S) and uses thereof
Inventor: SEROUSSI EYAL
IPC: C12Q1/68
Filed: 2006-06-28
Abstract: Disclosed is an isolated polynucleotide comprising the coding region of the ABCG2 nucleotide sequence shown in SEQ ID NO: 183, wherein the nucleotide sequence comprises a missense mutation that encodes a substitution of tyrosine-581 to serine (Y58IS). This polymorphism is a quantitative trait locus (QTL) affecting bovine milk fat and protein concentration.
Patent NZ-569354-A (NZ)
Title: Autologous bone harvest during osteotomy and bone drilling procedures
Inventor: RALPH JAMES D
IPC: A61B17/17
Filed: 2006-08-29
Abstract: Apparatus for collecting particulate bone, from a bone having a bone surface, for use in combination with a bone cutting or drilling tool during an osteotomy or bone drilling procedure is disclosed. The bone cutting or drilling tool has a diameter and a distal end with a bone cutting or drilling element extending distally from it. The bone cutting or drilling element has a collection module with a proximal end and a distal end and a housing. The housing comprises an inner wall, an outer wall, an end wall, a suction port, and a flexible portion. The inner wall has distal and proximal ends, and is sized for sealing and removable engagement of the proximal end of the collection module with the distal end of the bone cutting or drilling tool. The outer wall is coaxially disposed around the inner wall and spaced from the inner wall and has a distal end extending distally from the distal end of the inner wall. The end wall is affixed to and caps the distal end of the outer wall. The end wall has a slot through it, which is sufficiently larger than the diameter of the bone cutting or drilling element to permit the bone cutting or drilling element to extend through it and to allow suctioning through the slot of bone particulate from an operating site. The suction port is disposed between the inner wall and the outer wall and is in suctioning communication with the slot. The flexible portion is disposed around the housing and has proximal and distal ends. The proximal end is affixed to the proximal end of the outer wall and the distal end extends distally from the end wall. The distal end of the flexible portion comprises an open cylindrical tube. The flexible portion of the collection module allows the open distal end of the cylindrical tube to follow irregularities in the bone surface when the collection module is in sealing engagement with the distal end of the bone cutting or drilling tool.
Patent NZ-570455-A (NZ)
Title: Synthesis of sialic acid in plants
Inventor: PACCALET THOMAS
IPC: C12N5/10
Filed: 2007-02-09
Abstract: Provided is a method of synthesizing sialic acid comprising, i) providing a transgenic plant comprising a nucleotide sequence encoding microbial N-acetyl neuraminic acid (Neu5Ac) synthase, the nucleotide sequence operatively linked with a regulatory region that is active in the plant, and ii) growing the transgenic plant and expressing the nucleotide sequence thereby synthesizing sialic acid. The method can be used to produce sialylated proteins of interest in plants.
Patent NZ-582480-A (NZ)
Title: Glp-1-fc fusion protein formulation
Inventor: NG KINGMAN
IPC: A61K9/08
Filed: 2008-07-09
Abstract: Disclosed is a stable solution formulation comprising a therapeutically effective amount of a GLP-1-Fc fusion protein in citrate buffer with polysorbate-80 in the range of about 0.01% to 0.05% (w/v), mannitol 5 in the range of about 4.3 to 5.0% (w/v), and wherein the solution has a pH in the range of about pH 6 to 7.
Patent NZ-587701-A (NZ)
Title: Anti-trka antibodies and derivatives thereof
Inventor: BENIGNI FABIO
IPC: C07K16/28
Filed: 2009-02-04
Abstract: Disclosed are anti-TrkA antibodies with improved binding affinity to TrkA-IgG, a Nerve growth factor receptor. The disclosed antibodies are useful in treating Alzheimer's disease, cancer, diabetes, leprosy, pancreatitis and neuropathic pain, along with various other disorders. Further disclosed is a pharmaceutical composition comprising said antibody and another pharmaceutically active agent. Also disclosed is a nucleic acid encoding said antibody, a vector comprising said nucleic acid, and a non-human transgenic mammal that expresses said antibody.
Patent NZ-590887-A (NZ)
Title: Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
Inventor: WITYAK JOHN
IPC: A61K31/426
Filed: 2009-08-04
Abstract: Disclosed herein are 2-,4-,6-substituted pyrimidine compounds of formula I, wherein: · X and Y are N; · R1 is optionally substituted phenyl with 1-3 groups independently selected from halo, alkyl groups having 1 to 4 carbon atoms, trifluoromethyl, alkoxy groups having 1 to 4 carbon atoms, and hydroxyl; · L is chosen from -C(O)O-, -C(O)N(R3)-, -N(R3)C(O)-, and -S(O)2N(R3)-; · R2 is hydrogen; · R3 is chosen from hydrogen and lower alkyl; · R4 is chosen from hydrogen and optionally substituted lower alkyl; and · R5 is hydrogen, · provided that the compound of Formula I is not 6-pheny Ipyrimidine-4-carboxylic acid; 6-(4-fluorophenyl)-pyrimidine-4-carboxylic acid; methyl 6-phenylpyrimidine-4-carboxylate; ethyl 6-phenylpyrimidine-4-carboxylate; or 6-phenylpyrimidine-4-carboxamide processes for their preparation, compositions comprising said compounds and uses thereof. Said compounds are useful as kynurenine-3-monooxygenase inhibitors and are therefore useful in the treatment of Huntington's disease, Alzheimer's disease, Parkinson's disease, olivoponto cerebellar atrophy, non-Alzheimer's dementia, multi-infarctual dementia, cerebral amyotrophic lateral sclerosis, cerebral ischemia, cerebral hypoxia, spinal or head trauma and epilepsy.
Patent NZ-592973-A (NZ)
Title: Compositions and methods of using angiopoietin-like 4 protein
Inventor: BUNTING STUART
IPC: C07K16/00
Filed: 2011-05-20
Abstract: Disclosed is the use of an anti-ANGPTL4 antagonist antibody that binds to the C-terminal of ANGPTL4 in the manufacture of a medicament for inhibiting a biological activity of ANGPTL4 in hepatocytes or pre-hepatocytes, wherein said biological activity of ANGPTL4 is binding to avB5 or inducing cell proliferation.
Patent NZ-598072-A (NZ)
Title: Guidance system for fasteners
Inventor: WYWIALOWSKI BRUCE F
IPC: B25C1/08
Filed: 2005-05-03
Abstract: 598072 A fastener driving tool 10 for driving fasteners 12b toward a work surface, the fasteners 12b being collated by a plurality of sleeves 64b each having a lower end and a plurality of protrusions 12a protruding from each one of the plurality of sleeves 64b, each fastener having a tip with a predetermined exposed tip length, comprising a body having a forward end, a rear end, and a cylinder with an axis 28, a piston 30 mounted within the cylinder, and a chamber 34 formed between the piston 30 and the rear end of the tool body where the chamber 34 provides pressurized gas to drive the piston 30 axially forwardly, a driver blade 32 extending axially forwardly from the piston 30, a nosepiece 36 extending axially forwardly from the front end of the tool body, and a shear block mounted to the nosepiece 36. The fasteners 12b each have a tip and are collated by a plurality of sleeves 64b each having a lower end beyond which the tip may project up to ½ inch. The shear block provides an opening into the drive bore 38 for the fasteners 12b and collation sleeves 64b. The opening has a main channel sized for accommodating the fasteners 12b, and a tip channel of a fixed depth of up to about 1/2 inch deep for providing a clearance through which the tips can pass, there being a pair of shoulders at a forward end of the main channel for supporting the lower ends of the sleeves 64b. There is also a pair of rails spaced rearwardly from the pair of shoulders, where the rails are engageable with the protrusions of the collation sleeves 64b, a magazine 42 for guiding the fasteners 12b to the opening of the shear block, the magazine 42, the shear block and the nosepiece 36 being fixed with respect to each other, and a fastener guide 44 for guiding the fasteners 12b toward the work surface extending axially forwardly from the nosepiece 36 and the shear block. The fastener guide 44 is movable with respect to the nosepiece 36 and the shear block between an extended position and a retracted position. The drive bore 38 is formed by the shear block, the nosepiece 36 and the fastener guide 44 for guiding the fasteners 12b and the driver blade 32 toward the work surface.
Patent NZ-598156-A (NZ)
Title: Compositions and methods for treating gaucher disease
Inventor: DANIEL PETER F
IPC: A61K38/46
Filed: 2010-07-28
Abstract: Disclosed herein are methods and compositions for treating Gaucher disease with a glucocerebrosidase, such as velaglucerase. Additionally disclosed is method of identifying a subject suitable for treatment with an alternative glucocerebrosidase enzyme replacement therapy and compositions related to the diagnosis and treatment of the subject. Additionally disclosed is a pharmaceutical composition comprising velaglucerase, a lyoprotectant such as sucrose, a buffer salt such as sodium citrate and a stabilising agent such as polysorbate 20.
Patent NZ-598774-A (NZ)
Title: Direct and selective production of ethanol from acetic acid utilizing a platinum/tin catalyst
Inventor: JOHNSTON VICTOR J
IPC: C07C29/149
Filed: 2009-07-20
Abstract: Disclosed is a process for selective and direct formation of ethanol from a carbon source comprising: (a) converting the carbon source into acetic acid; and (b) contacting a feed stream containing the acetic acid and hydrogen in vapour form at a temperature of 200 degrees C to 300 degrees C with a hydrogenating catalyst containing a combination of platinum and tin on a catalyst support.
Patent NZ-601547-A (NZ)
Title: Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
Inventor: DOMINGUEZ CELIA
IPC: A61P25/16
Filed: 2011-01-20
Abstract: 601547 Certain heterocycle substituted pyrimidine derivatives are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington’s disease, Alzheimer’s disease, Parkinson’s disease, olivoponto cerebellar atrophy, non-Alzheimer’s dementia, multi-infarctual dementia, cerebral amyotrophic lateral sclerosis, cerebral ischemia, cerebral hypoxia, spinal or head trauma and epilepsy. Also described are methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity Compounds of the disclosure include: 3-[6-(3-Chloro-4-trifluoromethoxy-phenyl)-pyrimidin-4-yl]-4 H-[1,2,4]oxadiazol-5-one, 4-(3,4-difluorophenyl)-6-(1H-tetrazol-5-yl)-pyrimidine, 4-[6-(3,4-Dichloro-phenyl)-pyrimidin-4-yl]-piperazin-2-one, 4-(3-Chloro-phenyl)-6-pyrazol-1-yl-pyrimidine, 4-(3-Chloro-phenyI)-6-imidazoI-1-yl-pyrimidine, 4-(3,4-Dichloro-phenyl)-6-[1,2,4]triazol-1-yI-pyrimidine, 6-[6-(3,4-Dichloro-phenyl)-pyrimidin-4-yI]-N -methyI-nicotinamide, 4-(3,4-Dichloro-phenyl)-2-methyl-6-(4-methyl-oxazol-2-yl)-pyrimidine, 2-[6-(3-Chloro-phenyl)-pyrimidin-4-yI]-5 ,6-difluoro-1H-benzoimidazole, and 2-[6-(3-Chloro-phenyl)-pyrimidin-4-yI]-benzooxazole.